Week in Review: China Pharmas Make Cross-Border Deals with the West
December 07, 2013 at 05:02 AM EST
The commercial arm of Hebei Medical University in-licensed China rights to a pre-clinical leukemia-targeting molecule from Sareum Holdings plc of Britain; JHL Biotech of Taiwan acquired non-exclusive rights a mammalian cell line technology developed by Switzerland’s Selexis; Beijing Union, a subsidiary of the Chinese Academy of Medical Sciences, signed a MOU to use a neuroimaging platform that diagnoses dementia developed by IXICO of Britain; China Pioneer Pharma paid $5.7 million to expand its China distribution agreement with NovaBay Pharma of California for antimicrobial products; Zhejiang Hisun Pharma will raise at least $328 million in a private placement, which it will use to expand capacity; and Helsinn Group, a Swiss pharma that specializes in supportive cancer care, has opened a China representative office in Beijing to acquire products. More details…. Stock Symbols: (AIM: SAR) (HK: 1345) (NYSE: NBY) (SHA: 600267) Share this with colleagues: // //